Active Research
-
ABX464-107: A randomized, double-blind, multicenter phase III study to evaluate the long-term efficacy and safety of ABX464 25 mg or 50 mg once daily as a maintenance therapy in subjects with moderately to severely active ulcerative colitis.
Primary Investigator: Huang, MD, Clifton
IRB ID: 2022-103 (OPEN)
-
CNTO1959PBCRD3007, A Phase 3, Multicenter, Randomized, Platform Study of p19 Inhibition of the IL-23 Pathway to Establish Efficacy in Pediatric Crohn’s Disease (MACARONI-23) (Intervention Specific Appendix to Master Protocol PLATFORMPBCRD3001/I6T-MC-PIBD)
Primary Investigator: Huang, MD, Clifton
IRB ID: 2024-064 (OPEN)
-
I6T-MC-AMAY, A Phase 3, Multicenter, Randomized, Platform Study of p19 Inhibition of the IL-23 Pathway to Establish Efficacy in Pediatric Crohn’s Disease (ISA Title: A Phase 3, Multicenter, Randomized Clinical Study to Evaluate Mirikizumab inPediatric Crohn’s Disease)
Primary Investigator: Huang, MD, Clifton
IRB ID: 2024-065 (OPEN)
-
KiteLock™ RCT: SAFETY AND EFFECTIVENESS OF 4% TETRASODIUM ETHYLENEDIAMINETETRAACETIC ACID CATHETER LOCK SOLUTION IN PREVENTING CENTRAL VENOUS CATHETER OCCLUSIONS IN CHILDREN WITH INTESTINAL FAILURE: A RANDOMIZED CONTROLLED TRIAL
Primary Investigator: Osuntokun MD, Bankole Oluseyi
IRB ID: 2024-035 (OPEN)
-
KITELOCK™ USE FOLLOWING PARTICIPATION IN STUDY: SAFETY AND EFFECTIVENESS OF 4% TETRASODIUM ETHYLENEDIAMINETETRAACETIC ACID CATHETER LOCK SOLUTION IN PREVENTING CENTRAL VENOUS CATHETER OCCLUSIONS IN CHILDREN WITH INTESTINAL FAILURE: A RANDOMIZED CONTROLLED TRIAL – KiteLock Arm
Primary Investigator: Osuntokun MD, Bankole Oluseyi
IRB ID: 2025-108 (OPEN)
-
PLATFORMPBCRD3001/I6T-MC-PIBD, A Phase 3, Multicenter, Randomized, Platform Study of p19 Inhibition of the IL-23 Pathway to Establish Efficacy in Pediatric Crohn’s Disease
Primary Investigator: Huang, MD, Clifton
IRB ID: 2024-063 (OPEN)
-
Regeneron_R668-EE-2423_Osuntokun: A Randomized Study Evaluating 2 Dose Regimens of Dupilumab in Children ≥6 Months of Age Weighing ≥5 to <15 Kg with Active Eosinophilic Esophagitis
Primary Investigator: Osuntokun MD, Bankole Oluseyi
IRB ID: Regeneron_R668-EE-2423_Osuntokun (OPEN)